Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants ... their mothers did not receive a maternal RSV vaccine.

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody ... to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or ...

The Food and Drug Administration on Monday approved Merck's shot designed to protect ... in the market are waiting for a meeting of outside vaccine advisors to the Centers for Disease Control ...

Merck said in a release that it expects orders ... All of the companies in the market are waiting for a meeting of outside vaccine advisors to the Centers for Disease Control and Prevention ...